AbbVie (ABBV)
(Delayed Data from NYSE)
$167.80 USD
-1.74 (-1.03%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $167.01 -0.79 (-0.47%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Earnings News For ABBV
-
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
-
Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline
-
AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs
-
AbbVie (ABBV) Q4 Earnings and Revenues Top Estimates
-
AbbVie: Q4 Earnings Snapshot
-
AbbVie: Q4 Earnings Snapshot
-
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
-
AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?
-
Earnings Preview: AbbVie (ABBV) Q4 Earnings Expected to Decline
-
AbbVie (ABBV) Q3 Earnings Beat, Shares Down Despite Raised View
-
AbbVie (ABBV) Q3 Earnings and Revenues Beat Estimates
-
AbbVie: Q3 Earnings Snapshot
-
AbbVie Reports Third-Quarter 2023 Financial Results
-
AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?
-
Earnings Preview: AbbVie (ABBV) Q3 Earnings Expected to Decline
-
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View
-
AbbVie (ABBV) Beats Q2 Earnings and Revenue Estimates
-
AbbVie: Q2 Earnings Snapshot
-
AbbVie Reports Second-Quarter 2023 Financial Results
-
Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales?
-
AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?
-
Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for
-
AbbVie (ABBV) Q1 Earnings Beat, Skyrizi Sales Underperform
-
AbbVie (ABBV) Q1 Earnings and Revenues Top Estimates
-
AbbVie: Q1 Earnings Snapshot